Eli Lilly profits more than double as weight-loss drug sales soar

Eli Lilly's impressive profit growth signals a significant shift in consumer health priorities, with weight management becoming a focal point for many. The success of Zepbound not only highlights the efficacy of the drug but also the broader market potential for obesity treatments. As healthcare systems increasingly prioritize preventive measures, companies like Eli Lilly may find themselves at the forefront of a lucrative sector.